These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 1280536

  • 1. Lack of evidence for a high-affinity sarcosinamide carrier or a catecholamine carrier in Calu-1 lung-cancer cells, HT-29 colon-cancer cells, and DHF fibroblasts.
    Malapetsa A, Bramson JL, Noë AJ, Panasci LC.
    Cancer Chemother Pharmacol; 1992; 31(2):146-50. PubMed ID: 1280536
    [Abstract] [Full Text] [Related]

  • 2. Transport of amino acid amide sarcosinamide and sarcosinamide chloroethylnitrosourea in human glioma SK-MG-1 cells.
    Skalski V, Feindel W, Panasci LC.
    Cancer Res; 1990 May 15; 50(10):3062-6. PubMed ID: 1692254
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells.
    Skalski V, Yarosh DB, Batist G, Gros P, Feindel W, Kopriva D, Panasci LC.
    Mol Pharmacol; 1990 Sep 15; 38(3):299-305. PubMed ID: 2402223
    [Abstract] [Full Text] [Related]

  • 4. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system.
    Noë AJ, Malapetsa A, Panasci LC.
    Mol Pharmacol; 1993 Jul 15; 44(1):204-9. PubMed ID: 8341272
    [Abstract] [Full Text] [Related]

  • 5. The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport.
    Skalski V, Feindel W, Panasci LC.
    J Neurooncol; 1989 Jul 15; 7(2):189-93. PubMed ID: 2476532
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU.
    Panasci LC, Dufour M, Chevalier L, Isabel G, Lazarus P, McQuillan A, Arbit E, Brem S, Feindel W.
    Cancer Chemother Pharmacol; 1985 Jul 15; 14(2):156-9. PubMed ID: 3971480
    [Abstract] [Full Text] [Related]

  • 14. Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1.
    Schipper HM, Skalski V, Panasci LC, Wang E.
    Cancer Chemother Pharmacol; 1990 Jul 15; 26(5):383-6. PubMed ID: 2208582
    [Abstract] [Full Text] [Related]

  • 15. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
    Huynh H, Nguyen TH, Panasci L, Do P.
    Cancer; 2004 Dec 15; 101(12):2881-91. PubMed ID: 15529313
    [Abstract] [Full Text] [Related]

  • 16. Synthesis of "no-carrier-added" carbon-11 SarCNU: the sarcosinamide analog of the chemotherapeutic agent BCNU.
    Conway T, Diksic M.
    J Nucl Med; 1988 Dec 15; 29(12):1957-60. PubMed ID: 3193209
    [Abstract] [Full Text] [Related]

  • 17. Does the carrier of chromaffin granules transport the protonated or the uncharged species of catecholamines?
    Kobold G, Langer R, Burger A.
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov 15; 331(2-3):209-19. PubMed ID: 3003589
    [Abstract] [Full Text] [Related]

  • 18. Glycerol uptake in HCT-15 human colon cancer cell line by Na(+)-dependent carrier-mediated transport.
    Fujimoto N, Inoue K, Hayashi Y, Yuasa H.
    Biol Pharm Bull; 2006 Jan 15; 29(1):150-4. PubMed ID: 16394529
    [Abstract] [Full Text] [Related]

  • 19. Regulation of taurine transport in human colon carcinoma cell lines (HT-29 and Caco-2) by protein kinase C.
    Brandsch M, Miyamoto Y, Ganapathy V, Leibach FH.
    Am J Physiol; 1993 May 15; 264(5 Pt 1):G939-46. PubMed ID: 8498520
    [Abstract] [Full Text] [Related]

  • 20. Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines.
    Chen ZP, McQuillan A, Mohr G, Panasci LC.
    Neurosurgery; 1998 May 15; 42(5):1112-9. PubMed ID: 9588557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.